This was further investigated in an elegant study by Cheng et al. using highly multiplexed peptide-MHC tetramers, identifying 91 different HBV and tumour antigen-specific T cell specificities, to show that patients with higher frequencies of intratumoral antigen-specific CD8+ TRM had a longer relapse-free survival [115]. This evidence concerns the gene CD8A and neoplasm.